General
Preferred name
ZONISAMIDE
Synonyms
Ad 810 ()
Zonisamide sodium ()
Zonisamide (sodium) ()
AD 810 sodium ()
CI 912 sodium ()
CI 912 ()
Zonegran,CI-912,AD 810 ()
N03AX15 ()
CI-912 ()
Excegran ()
PD-110843 ()
Zonisade ()
Zonegran ()
AD-810 ()
Zonisamide mylan ()
Zonisamida ()
Zonisamide-13C2,15N ()
P&D ID
PD002942
CAS
68291-97-4
1188265-58-8
Tags
available
drug
Approved by
EMA
PMDA
FDA
First approval
2000
Drug indication
Epilepsy
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Zonisamide is a sulfonamide and therefore unrelated to other seizure medications. The mechanism is not know but it may block sodium and calcium channels. Blocking of these channels may prevent neuronal hypersynchronization. Sonisamide has also been found to potentiate dopaminergic and serotonergic neurotransmission but does not appear to potentiate syanptic activity by GABA (gamma amino butyric acid).
ABSORPTION The absorption is rapid with a time to peak concentration of 2.8-3.9 hours. Food has not effect on bioavailability.
DESCRIPTION Zonisamide is a sulfonamide anticonvulsant. (GtoPdb)
DESCRIPTION Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson¡¯s disease and cardiac hypertrophy[1][2][3][4].
PRICE 29
DESCRIPTION Dual CaV1.x and CaV2.x blocker (Tocris Bioactive Compound Library)
DESCRIPTION Blocks voltage-sensitive Na+ and Ca2+ channels (T-type) (Tocriscreen Plus)
DESCRIPTION Blocks voltage-sensitive Na+ and Ca2+ channels (T-type) (Tocriscreen Total)
DESCRIPTION Zonisamide is a sulfonamide anticonvulsant. It is a carbonic anhydrase inhibitor. It act by blocking repetitive firing of voltage-gated sodium channels leading to a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. It is used as adjunctive treatment of partial seizures in adults with epilepsy. (Enamine Bioactive Compounds)
DESCRIPTION Zonisamide (AD 810), a sulfonamide anticonvulsant, is approved for use as an adjunctive treatment in adults with partial-onset seizures. It may inhibit a carbonic anhydrase although this is not one of the main mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels results in a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may lower the uptake of the inhibitory neurotransmitter GABA while increasing the uptake of the excitatory neurotransmitter glutamate. (TargetMol Bioactive Compound Library)
DESCRIPTION Antiepileptic; effective in various animal epilepsy models and in humans with both partial and generalized epileptic seizures (LOPAC library)
Cell lines
0
Organisms
2
Compound Sets
33
Cayman Chemical Bioactives
24183
28807
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL750
ChEMBL Drugs
CHEMBL750
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00909
DrugBank Approved Drugs
DB00909
DrugCentral
2872
DrugCentral Approved Drugs
2872
DrugMAP
DM0DTF7
DrugMAP Approved Drugs
DM0DTF7
DrugMatrix
Enamine Bioactive Compounds
EBC-11182
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101701
Guide to Pharmacology
7047
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL750
MedChem Express Bioactive Compound Library
HY-B0124
NCATS Inxight Approved Drugs
459384H98V
NIH Clinical Collections (NCC)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Zonisamide
TargetMol Bioactive Compound Library
T0267
The Spectrum Collection
Tocris Bioactive Compound Library
2625
Tocriscreen Plus
2625
Tocriscreen Total
ZINC Tool Compounds
ZINC000000004321
External IDs
56
Properties
(calculated by RDKit )
Molecular Weight
212.03
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
2
cLogP
0.62
TPSA
86.19
Fraction CSP3
0.12
Chiral centers
0.0
Largest ring
6.0
QED
0.79
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Ion Channels
Target
Calcium Channel
Sodium Channel
Sodium channel alpha subunit
Carbonic Anhydrase
CA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9, CACNA1G, CACNA1H, CACNA1I, MAOA, MAOB, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A
Apoptosis
Pathway
Membrane Transporter/Ion Channel
Neuronal Signaling
Metabolism
Metabolic Enzyme/Protease
MOA
voltage-gated sodium channel blocker
voltage-gated calcium channel blocker
sodium channel blocker, T-type calcium channel blocker
Primary Target
Other Channel Modulators
Indication
seizures, epilepsy
Therapeutic Class
Analgesics
Source data